Species loss and biological collapse threaten humanity just as much as climate change. Since 1992, the Convention on Biological Diversity (CBD) has become a hallmark of sustainable development across the globe. The CBD and its three goals – protection of biodiversity, sustainable use of biodiversity, and fair and equitable benefit sharing – became a hallmark of sustainable development that involved the entire globe. Over the next 20 years, more treaties to the CBD were added, e.g. the Cartagena Protocol and the Aichi Targets. But what have the political treaties accomplished? What were the trade-offs? The biodiversity research community has experienced unfortunate unintended consequences and a new push to include DNA sequence information in the CBD in 2020 could have serious consequences of its own. The talk will explore the tension between global goals and practical outcomes and present ideas for strengthening conservation of biodiversity without undermining the science that makes it all possible.
Snacks and one drink are included. Please register via Eventbrite.
OLSx is a distinctive, international and open event series tapping on relevant economic, social and environmental issues. We are inviting an accomplished speaker for each event, who will share her or his perspectives on pressing topics. Afterwards, the audience is invited to continue the conversation – during the Q&A with our speaker and of course amongst each other during the networking session with drinks and snacks.
With: Dr. Amber Hartman Scholz, Deputy to the Director of the Leibniz Institute DSMZ (German Collection for Microorganisms and Cell Cultures)
In cooperation with:wizemann.space, Wirtschaftsförderung Stuttgart
Dr. Amber Hartman Scholz
Dr. Amber Hartman Scholz is the Deputy to the Director at the Leibniz Institute DSMZ, the German Collection for Microorganisms and Cell Cultures, in Braunschweig, Germany. She headed the team that led to the DSMZ becoming the first Registered Collection under the Nagoya Protocol in the European Union, demonstrating the collection’s voluntary and stringent compliance with EU Regulation 511/2014. Her broader work at the DSMZ focuses on internationalization, strategic development, and science policy. Dr. Scholz has broad experience in science and policy through her work in the United States at the White House Office of Science and Technology Policy (OSTP) as Executive Director to the President’s Council of Advisors on Science and Technology from, the National Cancer Institute as a Policy Advisor, and as a Policy Consultant to the California State Senate Environmental Quality Committee. She received her PhD in Biology with a focus on microbiology and genomics in 2009 from the Johns Hopkins University.